Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000692042 | SCV000819849 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2024-10-10 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003144514 | SCV003834516 | uncertain significance | not provided | 2022-10-09 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004965674 | SCV005536110 | uncertain significance | Inborn genetic diseases | 2024-11-20 | criteria provided, single submitter | clinical testing | The c.3538A>G (p.I1180V) alteration is located in exon 9 (coding exon 9) of the ATRX gene. This alteration results from a A to G substitution at nucleotide position 3538, causing the isoleucine (I) at amino acid position 1180 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000692042 | SCV002087298 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2019-10-28 | no assertion criteria provided | clinical testing |